

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Sommadossi <i>et al.</i>	Confirmation No.:	1388
Serial No.:	10/602,691	Art Unit:	1623
Filed:	June 20, 2003	Examiner:	T. McIntosh III
For:	METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS	Attorney Docket No: (CAM: (IDX 1007 CON 1)	11874-043-999 417451-999043

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Petitioner, Idenix Pharmaceuticals, Inc., is an assignee of less than the entire right, title and interest in and to the above identified application by virtue of an assignment which was recorded on September 13, 2001 at reel 012162 frame 0294.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of U.S. Patent No. 7,148,206, and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 7,148,206.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of U.S. Patent No. 7,148,206 in the event that one or more of said patents later expire for failure to pay a maintenance fee, are held unenforceable, are found invalid, are statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), have all claims canceled by a reexamination certificate, or are otherwise terminated prior to the expiration of the full statutory term, except for the separation of legal title stated above.


Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is

empowered to act on behalf of Idenix Pharmaceuticals, Inc.

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 12th day of June, 2008.

Idenix Pharmaceuticals, Inc.

By: 

Name: John F. Weidenbruch, Esq.
Position: Executive Vice President and General Counsel